Navigation Links
Major clinical trial finds no link between genetic risk factors and 2 top wet AMD treatments
Date:2/12/2013

SAN FRANCISCO February 12, 2013 New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis and Avastin, the two medications most widely used to treat the "wet" form of AMD. This new data from the Comparison of AMD Treatment Trials (CATT), published online in Ophthalmology, the journal of the American Academy of Ophthalmology, found no significant association between four gene variants and outcomes that measured the patients' responses to treatment.

The CATT genetics research team wanted to learn whether the major AMD risk genes could be useful in tailoring treatment with Avastin and Lucentis to individual patients' needs to boost treatment effectiveness and safety for patients. The main CATT study had confirmed that both medications significantly reduce or even reverse vision loss in many patients with wet AMD, but that study also found that treatment effectiveness varied among patients. The CATT genetics study, led by Stephanie Hagstrom, Ph.D., at the Cole Eye Institute at the Cleveland Clinic, clearly showed that the major AMD risk alleles do not predict patients' response to treatment.

This genetics study cohort comprised 73 percent of the 1,149 CATT participants. Cohort patients were evaluated for four gene variants linked to AMD risk: CFH, ARMS2, HTRA1, and C3. The patients' genotypes were then compared to their responses to treatment with Lucentis or Avastin. Both medications are anti-vascular epithelial growth factor (anti-VEGF) therapies that work in similar ways to reduce or prevent abnormal blood vessel growth and leakage. The researchers found no significant associations among the four gene variants and the outcomes that measured the patients' responses to treatm
'/>"/>

Contact: Mary Wade
mwade@aao.org
415-447-0221
American Academy of Ophthalmology
Source:Eurekalert

Page: 1 2

Related biology news :

1. Global Companion Diagnostic Market Worth $19.3 billion by 2023: What it Takes to Become a Major Companion Diagnostic Player
2. Genetics plays major role in victimization in elementary school
3. Major cuts to surging CO2 emissions are needed now, not down the road, study finds
4. Majority of Americans doubt Congress and White House can avoid fiscal cliff
5. Mercury releases contaminate ocean fish: Dartmouth-led effort publishes major findings
6. Major breakthrough in deciphering bread wheats genetic code
7. Major international push to maximize bioscience research to help worlds poorest farmers
8. Baylor University scientist receives major grants for health research on 1991 Gulf War veterans
9. British Library leads the way for sharing data as major institutions sign up to DataCite
10. Whitehead scientists identify major flaw in standard approach to global gene expression analysis
11. Major changes needed to protect Australias species and ecosystems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
(Date:1/22/2015)... Washington , January 20, 2015 Investorideas.com, ... tech stocks, releases video from the CES 2015 (Consumer Electronics ... Apollo Robbins . Apollo shows how easily ... smart wallet, a product of NXT-ID, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3
... have discovered a gene in plants that disrupts fertilization ... both the female and male reproductive cells. Their ... in the journal Current Biology, has been named the ... properties. Mutations that do not allow fertilization are ...
... of Grenoble, in France, have discovered that ... by doxorubicin and trastuzumab exposures. The research ... protects against acute chemotherapy toxicity in isolated ... January 2008 issue of Experimental Biology and ...
... - A group of signaling proteins known as Wnt ... muscle and other tissues - depend on a complex ... tissue-building cell sites, according to a study at Cincinnati ... the Retromer Complex - breaks down, the delivery of ...
Cached Biology News:Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3A search for protection against chemotherapy cardiotoxicity 2Certain diseases, birth defects may be linked to failure of protein recycling system 2
(Date:1/22/2015)... CO / Rootstown, OH (PRWEB) January 22, 2015 ... detection platform, announced today that it has received AOAC-PTM Certifications ... O45, O1O3, O111, O121, and O145; collectively referred to as ... coli) O157, at 1 colony forming unit (cfu) per 325 ...
(Date:1/22/2015)... 2015 Selexis SA, a serial innovation ... Banks (RCBs) used for drug discovery to commercial manufacturing, ... include Next-Generation Sequencing (NGS) data packages. The ... manufacturing by ensuring the integrity of the gene, validation ...
(Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
(Date:12/24/2014)...  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical solutions ... the Company closed its previously announced private placement ... W. Schuler , Birchview Fund LLC and several ... offering expenses.  The proceeds will be used for ...
Breaking Biology Technology:Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... BioTrends Research Group, Inc. finds that with the introduction ... the treatment of multiple sclerosis (MS), neurologists anticipate major shifts ... the launch of Gilenya, trial and uptake of Extavia, a ... tempered due to the perception that Extavia is a "me ...
... 2010 Prince of Wales Hospital in Hong Kong, China, ... treating cancer patients using the UNIQUE™ medical linear accelerator from ... for the first time last week, to deliver an image-guided ... in the lower part of the throat near the larynx. ...
... Scientists from Pacific Biosciences of California, Inc. (NASDAQ: ... molecule, real-time (SMRT) DNA sequencing technology to rapidly characterize ... in Haiti. Published Thursday in the New ... first whole genome sequence analysis and most detailed genetic ...
Cached Biology Technology:With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 2With the Recent Launch of Novartis's Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch 3Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System 2Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System 3Prince of Wales Hospital in Hong Kong First in Asia to Offer Cancer Patients Image-Guided RapidArc® Radiotherapy Using the UNIQUE™ Radiotherapy System 4Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 2Pacific Biosciences and Harvard scientists decode genome of Haitian cholera pathogen 3
... iLink makes it easy to supply microplates, ... Developed with operator convenience in mind, iLink ... ease of use. The iLink software is ... assays or sub-assays, that can be copied ...
... laboratory's requirements for data management and quality control. ... ... ... software for Staccato Systems and custom Allegro Modules allowing for the simple interface with more than ...
... demands continue to grow, the need for ... has become necessary, especially when discerning very ... innovative C1si Confocal Microscope System gives you ... capability not available in conventional confocal systems, ...
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
Biology Products: